Bone-targeted therapy: Phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 6, 2008, Pages 532-538

  Amato, Robert J ^a   Hernandez McClain, Joan ^a   Henary, Haby ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Bone metastasis; Bone targeted therapy; Chemohormonal therapy; Hormone refractory prostate cancer; Strontium 89

Indexed keywords

DOXORUBICIN; ESTRAMUSTINE; HYDROCORTISONE; KETOCONAZOLE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; STRONTIUM 89; SUCRALFATE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANKLE EDEMA; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; GASTROINTESTINAL SYMPTOM; HEARING LOSS; HUMAN; HYPOPHOSPHATEMIA; LEG ISCHEMIA; LEUKOPENIA; LUNG EMBOLISM; MALE; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PROSTATE ADENOCARCINOMA; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TINNITUS; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DOXORUBICIN; ESTRAMUSTINE; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; PACLITAXEL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STRONTIUM RADIOISOTOPES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 58149267548     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318172aa92     Document Type: Article

References (26)

1. Petrylak D, Tangen C, Hussain M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
2. Tannock I, de Wit R, Berry W, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
3. Roth BJ, Yeap BY, Wilding G, et al. Taxol in advanced, hormone-refractory carcinoma of the prostate-a phase II trial of the Eastern Cooperative Oncology Group. Cancer. 1993;72:2457-2460.
4. Chiappino I, Destefanis P, Addeo A, et al. Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer. Am J Clin Oncol. 2007;30:234-238.
5. Vaishampayan U, Fontana J, Du W, et al. An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer. Urology. 2002;60:1050-1054.
6. Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1997;15:3156-3163.
7. Haas N, Roth B, Garay C, et al. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology. 2001;58:59-64.
8. Kelly WK, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol. 2001;19:44-53.
9. Berry W, Friedland D, Fleagle J, et al. A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. Clin Genitourin Cancer. 2006;5:131-137.
10. Solit DB, Morris M, Slovin S, et al. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer. 2003;98:1842-1848.
11. Millikan R, Thall PF, Lee SJ, et al. Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol. 2003;21:878-883.
12. Thall PF, Logothetis C, Pagliaro LC, et al. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst. 2007;99:1613-1622.
13. Fizazi K, Le Maitre A, Hudes G, et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol. 2007;8:994-1000.
14. Kemeny N, Fong Y. Treatment of liver metastases. In: Holland J, Bast R, Morton D, et al, eds. Cancer Medicine, 4th ed. vol. 2. Baltimore, MD: Williams and Wilkins; 1997:1941-1943.
15. Putnam JB, Roth JA, Wesley MN, et al. Survival following aggressive resection of pulmonary metastases from osteogenic-sarcoma-analysis of prognostic factors. Ann Thorac Surg. 1983;36:516-523.
16. Koeneman K, Yeung F, Chung L. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate. 1999;39:246-261.
17. Glotzman D. Mechanisms of the development of osteoblastic metastasis. Cancer. 1997;80:1581-1587.
18. Robinson RG, Blake GM, Preston DF, et al. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics. 1989;9:271-281.
19. Nightengale B, Brune M, Blizzard SP, et al. Strontium chloride Sr-89 for treating pain from metastatic bone-disease. Am J Health Syst Pharm. 1995;52:2189-2195.
20. Tu S, Delpassand ES, Jones D, et al. Strontium-89 combined with doxorubicin in the treatment of cancer patients with androgen-independent prostate cancer. Urol Oncol. 1996;2:191-197.
21. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357:336-341.
22. Tu SM, Kim J, Pagliaro LC, et al. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005;23:7904-7910.
23. Akerley W, Butera J, Wehbe T, et al. A multi-institutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer. 2002;94:1654-1660.
24. Kaplan E, Meier P. Nonparametic estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
25. Ellerhorst J, Tu S, Amato R, et al. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res. 1997;3:2371-2376.
26. Savarese D, Halabi S, Hars V, et al. Phase II study docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol. 2001;19:2509-2516.